Log In
Print this Print this

Dll4 inhibitor, enoticumab (REGN421, SAR153192)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionHuman mAb targeting delta-like ligand 4 (DLL4)
Molecular Target Delta-like 4 (DLL4)
Mechanism of ActionDelta-like ligand 4 (Dll4) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today